MHRA gives Bristol Labs the all-clear

The reinstatement of the manufacturing license of a U.K. generics producer should help relieve drug shortages there. (Bristol Laboratories)

Bristol Laboratories is back in business in the U.K.

The U.K. generic drug maker, whose partial suspension by European regulators in 2017 led to shortages of some drugs, has passed its latest Medicines and Healthcare products Regulatory Agency (MHRA) inspection.

Bristol Director of Quality and Regulatory Affairs Priti Ramachandran said the company “welcomes the full reinstatement of GMP status for our UK manufacturing facilities, following successful MHRA inspections," Manufacturing Chemist reports

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

RELATED: U.K. pulls manufacturing authorization from Bristol Laboratories 

The suspension over quality and data issues was imposed two years ago following an inspection of the company’s facility in Luton. It resulted in the company producing only products considered medically critical to EU members. It was extended in 2018 when follow-up inspections found ongoing issues.

Ramachandran said the status change would allow Bristol to focus on maintaining supplies when Brexit is complete. Drugmakers have been required to build up their supplies in the U.K. of critical drugs to try to avoid shortages if Brexit results in delays delivering medicines from manufacturing facilities outside the country.

Suggested Articles

With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.

Akorn has been slammed with another FDA warning letter even as it is in the process of renegotiating its loans with lenders.

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.